Midwest Wealth Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
$1.57M Buy
21,450
+2,247
+12% +$151K 0.95% 59
2021
Q4
$1.2M Buy
19,203
+1,479
+8% +$86.8K 0.75% 71
2021
Q3
$1.05M Buy
17,724
+996
+6% +$65.6K 0.72% 73
2021
Q2
$1.12M Buy
16,728
+2,541
+18% +$166K 0.8% 63
2021
Q1
$896K Buy
14,187
+2,114
+18% +$132K 0.73% 66
2020
Q4
$749K Buy
+12,073
New +$742K 0.68% 65

Other funds holding BMY

Midwest Wealth Management's BMY Position: Q1 2022 in Review

Midwest Wealth Management increased its Bristol-Myers Squibb (BMY) stake by 12% in Q1 2022, buying an estimated $151K and bringing the position to 21,450 shares worth $1.57M. The position accounts for 0.95% of the portfolio, ranked #59.

Midwest Wealth Management first reported a position in BMY in Q4 2020 and has held it in 6 quarters since. 2,515 funds tracked by Wall St. Rank hold BMY as of Q1 2022.

  • Midwest Wealth Management held 21,450 shares of Bristol-Myers Squibb worth $1.57M as of Q1 2022.
  • Midwest Wealth Management bought 2,247 Bristol-Myers Squibb shares in Q1 2022, an estimated $151K.
  • Bristol-Myers Squibb made up 0.95% of Midwest Wealth Management's portfolio in Q1 2022, its #59 holding.
  • Midwest Wealth Management first reported a position in Bristol-Myers Squibb in Q4 2020 and has held it in 6 quarters since.
  • 2,515 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2022.

Based on Midwest Wealth Management's 13F filing for Q1 2022, filed 25 May 2022.